Clinical Scorecard: The Role of Hemoglobin and Anemia in Preventing Dementia—Revisiting a Well-Known Protein
At a Glance
Category
Detail
Condition
Dementia and its association with anemia
Key Mechanisms
Impaired oxygen transport to the brain, altered cerebral hemodynamics, iron and vitamin B metabolism disturbances, and Alzheimer pathology interaction
Target Population
Aging populations, especially those with anemia
Care Setting
Population-based and clinical settings focusing on aging and neurodegenerative disease prevention
Key Highlights
Anemia is associated with a 66% increased relative risk of developing dementia over approximately 9 years.
A J-shaped relationship exists between hemoglobin levels and dementia risk, with increased risk below ~14 g/dL.
Anemia interacts additively with plasma biomarkers of neurodegeneration (phosphorylated tau 217, neurofilament light chain, glial fibrillary acidic protein) to increase dementia risk 3- to 4-fold.
Guideline-Based Recommendations
Diagnosis
Assess hemoglobin levels continuously to identify anemia and risk thresholds (~14 g/dL).
Evaluate plasma biomarkers of neurodegeneration in patients with anemia for risk stratification.
Management
Investigate and address underlying causes of anemia, including iron and vitamin B deficiencies.
Consider interventions targeting oxygen delivery and cerebral hemodynamics to preserve neuronal health.
Monitoring & Follow-up
Long-term follow-up of hemoglobin levels and cognitive status in at-risk populations.
Monitor plasma biomarkers related to neurodegeneration in patients with anemia.
Risks
Increased dementia risk with macrocytic and microcytic anemia compared to normocytic anemia.
Potential confounding effects of chronic diseases and nutritional deficiencies on anemia-dementia association.
Patient & Prescribing Data
Older adults with anemia, particularly those with low hemoglobin levels and elevated neurodegenerative biomarkers
Addressing anemia and its causes may reduce dementia risk; however, mechanistic and interventional studies are needed to guide therapy.
Clinical Best Practices
Screen aging patients for anemia and monitor hemoglobin levels regularly.
Evaluate iron status and vitamin B levels to identify treatable causes of anemia.
Incorporate biomarker assessments where available to better understand dementia risk.
Consider sex differences and geographic diversity when applying prevention strategies.
Promote research combining plasma and cerebrospinal fluid biomarkers with imaging and cognitive outcomes.
